Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2011

01-12-2011

Protective Effects of Indomethacin and Cyclophosphamide but Not of Infliximab on Liver Metabolic Changes Caused by Adjuvant-Induced Arthritis

Authors: Maria Angélica Raffaini Covas Pereira da Silva, Ciomar Aparecida Bersani-Amado, Emy Luiza Ishii-Iwamoto, Lívia Bracht, Silvana Martins Caparroz-Assef

Published in: Inflammation | Issue 6/2011

Login to get access

Abstract

In the study, indomethacin, cyclophosphamide, and infliximab were administered to adjuvant-induced arthritic rats to determine if they were able to prevent the abnormalities caused by arthritis on hepatic metabolism. The drugs were administered to arthritic rats, and at the clinical onset of arthritis (day 14 after adjuvant injection), the livers were perfused to evaluate gluconeogenesis, ureagenesis, oxygen uptake, l-lactate, pyruvate, and ammonia release from l-alanine. The effects of the drugs on body weight gain and the signs of arthritis (paw edema, appearance of secondary lesions, and weights of lymphoid tissues) were also evaluated. Cyclophosphamide could completely prevent liver metabolic changes and the inflammatory response. Indomethacin restored ureagenesis, minimized the decrease in gluconeogenesis, and exerted a partially beneficial effect on inflammatory reactions. Infliximab did not improve arthritis-induced liver metabolic alterations or inflammatory responses. These results suggest the participation of prostaglandins, but not TNF-α, on arthritis-induced liver metabolic alterations.
Literature
1.
Mackenzie, A.R., C.R. Pick, P.R. Sibley, and B.P. White. 1978. Suppression of rat adjuvant disease by cyclophosphamide pretreatment: Evidence for an antibody mediated component in the pathogenesis of the disease. Clinical and Experimental Immunology 32(1): 86–96.PubMed
2.
Konttinen, Y.T., S. Reitamo, A. Ranki, P. Hayry, U. Kankaanapaa, and O. Wegelius. 1981. Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis & Rheumatism 24: 71–79.CrossRef
3.
Naparstek, Y., J. Holoshitz, S. Eisenstein, T. Reshef, S. Rappaport, J. Chemke, A. Ben-Nun, and I.R. Cohen. 1982. Effector T lymphocyte line cells migrate to thymus and persist there. Nature 300: 262–264.PubMedCrossRef
4.
Keystone, E.C. 2005. B cells in rheumatoid arthritis: From hypothesis to the clinic. Rheumatology 44(supplement 2): ii8–ii12.PubMedCrossRef
5.
Stolina, M., B. Bolon, S. Middleton, D. Dwyer, H. Brown, D. Duryea, L. Zhu, A. Rohner, J. Pretorius, P. Kostenuik, U. Feige, and D. Zack. 2009. The evolving systemic and local biomarkers milieu at different stages of disease progression in rat adjuvant-induced arthritis. Journal of Clinical Immunology 29(2): 158–174.PubMedCrossRef
6.
Choy, E.H.S., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344: 907–916.PubMedCrossRef
7.
8.
Khale, P., J.G. Saal, and K. Schaudt. 1992. Determination of cytokines insynovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue. Annals of the Rheumatic Diseases 51: 731–734.CrossRef
9.
Hamada, K., E. Vannier, D.E. Smith, L.W. Abad, and R. Roubenoff. 2000. Inflammatory cachexia induces sarcoactive cytokine gene expression in a rat model of adjuvant arthritis. Journal of the Federation for the American Society for Experimental Biology 14: A572.
10.
Humes, J.L., R.J. Bonney, L. Pelus, M.E. Dahlgren, S.J. Sadowsky, F.A. Kuehl, and P. Davies. 1977. Macrophages synthesis and release prostaglandins in response to inflammatory stimuli. Nature 269: 149–151.PubMedCrossRef
11.
Sano, H., T. Hla, J.A. Maier, L.J. Crofford, J.P. Case, T. Maciag, and R.L. Wilder. 1992. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. The Journal of Clinical Investigation 89: 97–108.PubMedCrossRef
12.
Shanahan, J.C., L.W. Moreland, and R.H. Carter. 2003. Upcoming biologic agents for the treatment of rheumatic diseases. Current Opinion of Rheumatology 15: 226–236.CrossRef
13.
Walsmith, J., and R. Roubenoff. 2002. Cachexia in rheumatoid arthritis. International Journal of Cardiology 85: 89–99.PubMedCrossRef
14.
Billingham, M.E.J. 1983. Models of arthritis and the search for antirheumatic drugs. Pharmacology & Therapeutics 21: 399.CrossRef
15.
Brahm, E. 1991. Animal models of rheumatoid arthritis. Clues to etiology and treatment. Clinical orthopaedics and Related Research 265: 42–53.
16.
Caparroz-Assef, S.M., C.A. Bersani-Amado, E.A. Nascimento, A.M. Kelmer-Bracht, and E.L. Ishii-Iwamoto. 1998. Effects of the nonsteroidal anti-inflammatory drug nimesulide on energy metabolism in livers from adjuvant-induced arthritic rats. Research Communications in Molecular Pathology & Pharmacology 99(1): 93–116.
17.
Fedatto Jr., Z., A.M. Kelmer-Bracht, E.L. Ishii-Iwamoto, J. Constantin, and A. Bracht. 1999. Gluconeogenesis in the liver of arthritic rats. Cell Biochemistry and Function 17: 271–278.CrossRef
18.
Fedatto Jr., Z., E.L. Ishii-Iwamoto, S.M. Caparroz-Assef, G.E. Vicentin, A. Bracht, and A.M. Kelmer-Bracht. 2002. Glycogen levels and glycogen catabolism in livers from arthritic rats. Molecular and Cellular Biochemistry 229: 1–7.CrossRef
19.
Fedatto Jr., Z., E.L. Ishii-Iwamoto, C.A. Bersani-Amado, E.R.M. Maciel, A. Bracht, and A.M. Kelmer-Bracht. 2000. Glucose phosphorylation capacity and glycolysis in the liver of arthritic rats. Inflammation Research 49: 128–132.PubMedCrossRef
20.
Yassuda, P., A. Bracht, E.L. Ishii-Iwamoto, S.H. Lousano, L. Bracht, and A.M. Kelmer-Bracht. 2003. The urea cycle in the liver of arthritic rats. Molecular and Cellular Biochemistry 243: 97–106.CrossRef
21.
Caparroz-Assef, S.M., C.A. Bersani-Amado, A.M. Kelmer-Bracht, A. Bracht, and E.L. Ishii-Iwamoto. 2007. The metabolic changes caused by dexamethasone in the adjuvant-induced arthritis rats. Molecular and Cellular Biochemistry 302(1–2): 87–98.PubMedCrossRef
22.
Kelmer-Bracht, A.M., A.C. Broetto-Biazon, A.B. De Sa-Nakanishi, E.L. Ishii-Iwamoto, and A. Bracht. 2006. Low doses of tumour necrosis factor alpha and interleukin 1beta diminish hepatic gluconeogenesis from alanine in vivo. Basical & Clinical Pharmacology & Toxicology 99(5): 335–339.CrossRef
23.
Bendele, A.M., J. McComb, T. Gould, E.S. Chlipala, J. Seely, G. Kieft, J. Wolf, and C.K. Edwards. 1999. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflammation Research 48: 453–460.PubMedCrossRef
24.
Au, W., O. Sokowa, B. Kopnin, and F.E. Arrigi. 1980. Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro. Cytogenetics and Cell Genetics 26: 108–116.PubMedCrossRef
25.
Knight, D.M., H. Trinh, J. Le, S. Siegel, D. Shealy, M. McDonough, B. Scallon, M.A. Moore, J. Vilcek, P. Daddona, and J. Ghrayeb. 1993. Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Molecular Immunology 30: 1443–1453.PubMedCrossRef
26.
Fox, D.A. 2000. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor. Archives of Internal Medicine 160(4): 437–444.PubMedCrossRef
27.
Rosenthale, M.E. 1970. A comparative study of the Lewis and Sprague Dawley rat in adjuvant arthritis. Archives Internationales de Pharmacodynamie et de Therapie 188: 14–22.PubMed
28.
Walz, D.T., M.J. Dimartino, and A. Misher. 1971. Adjuvant-induced arthritis in rats. II. Drug effects on physiologic, biochemical and immunologic parameters. Journal of Pharmacology and Experimental Therapeutics 178: 223–231.PubMed
29.
Yamaguchi, Y., Y. Tanaka, K. Yamada, Y. Bandô, and M. Kunitomo. 1989. Abnormal lipid metabolism in adjuvant arthritic rats. Japanese Journal of Pharmacology 50: 377–386.PubMedCrossRef
30.
Gaffney, K., and D.G.I. Scott. 1998. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. British Journal of Rheumatology 37: 824–836.PubMedCrossRef
31.
Triantafillidis, J.K., A.E. Papalois, A. Parasi, E. Anagnostakis, S. Burnazos, A. Gikas, E.G. Merikas, E. Douzinas, M. Karagianni, and H. Sotiriou. 2005. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World Journal of Gastroenterology 11(43): 6843–6847.PubMed
32.
Onda, A., Y. Murata, B. Rydevik, K. Larsson, S. Kikuchi, and K. Olmarker. 2004. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine 29(17): 1857–1861.PubMedCrossRef
33.
Scholz, R., and T. Bücher. 1965. Hemoglobin-free perfusion of rat liver. In Control of energy metabolism, ed. B. Chance, R.W. Estabrook, and J.R. Williamson, 393–414. New York: Academic.
34.
Bergmeyer, H.U. 1974. Determination of urea with glutamate dehydrogenase as indicator enzyme. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 1794–1801. New York: Academic.
35.
Gutman, I., and A.W. Wahlefeld. 1974. (+)Lactate determination with lactate dehydrogenase and NAD+. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 1464–1468. New York: Academic.
36.
Czok, R., and W. Lamprecht. 1974. Pyruvate, phosphoenolpyruvate and glycerate-2-phosphate. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 1446–1451. New York: Academic.
37.
Bergmeyer, H.U., and E. Bernt. 1974. Glucose determination with glucose oxidase and peroxidase. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 1205–1212. New York: Academic.
38.
Kun, F., and E.B. Kearney. 1974. Ammonia. In Methods of enzymatic analysis, ed. H.U. Bergmeyer, 1801–1806. New York: Academic.
39.
Berenbaum, M.C., and I.N. Brown. 1963. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 200: 84.PubMedCrossRef
40.
Turk, J.L. 1973. Evidence for preferential effect of cyclophosphamide on B-cells. Proceedings of the Royal Society of Medicine 66: 805–808.PubMed
41.
Wang, B., and M.Z. Chen. 1998. Effects of indomethacin on secretory function of synoviocytes from adjuvant arthritic rats. International Journal of Tissue Reaction 20(3): 91–94.
42.
Kast, R.E. 2000. Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing tumor necrosis factor. Biomedicine & Pharmacotherapy 54: 168–169.CrossRef
43.
Ulcar, R., B.A. Peskar, R. Schuligoi, A. Heinemann, H.H. Kessler, B.I. Santner, and R. Amann. 2004. Cyclooxygenase inhibition in human monocytes increases endotoxin-induced TNFα without affecting cyclooxygenase-2 expression. European Journal of Pharmacology 501: 9–17.PubMedCrossRef
44.
Martel-Pelletier, J., J.P. Pelletier, and H. Fahmi. 2003. Cyclooxygenase-2 and prostaglandins in articular tissues. Seminars in Arthritis and Rheumatism 33: 155–167.PubMedCrossRef
45.
Kang, R.Y., J. Freire-Moar, E. Sigal, and C.Q. Chu. 1996. Expression of cyclooxygenase-2 in human and an animal model f rheumatoid arthritis. British Journal of Rheumatology 35: 711–718.PubMedCrossRef
46.
Anderson, G.D., S.D. Hauser, K.L. Mcgar, M.E. Bremer, P.C. Isakson, and S.A. Gregory. 1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. Journal of Clinical Investigation 97: 2672–2679.PubMedCrossRef
47.
Feldmann, M., and R.N. Maini. 1999. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology 38(suppl 2): 3–7.PubMed
48.
Szekanecz, Z., M.M. Halloran, M.V. Volin, J.M. Woods, R.M. Strieter, K. Haines, S.L. Kunkel, M.D. Burdick, and A. Koch. 2000. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis and Rheumatism 43: 1266–1277.PubMedCrossRef
49.
Roubenoff, R., R.A. Roubenoff, J.G. Cannon, and J.J. Kehayias. 1994. Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. Journal of Clinical Investigation 93: 2379–2386.PubMedCrossRef
50.
Roubenoff, R., L.M. Freemann, D.E. Smith, L.W. Abad, C.A. Dinarello, and J.J. Kehayias. 1997. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis and Rheumatism 40: 534–539.PubMedCrossRef
51.
Feldmann, M., and R.N. Maini. 2003. Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 9: 1245–1250.PubMedCrossRef
52.
Doucolombier, V., E. Solau, P. Coquerelle, E. Houvenagel, J.L. Siame, X. Desprez, P. Fauquert, M.H. Guyot, B. Delcambre, and R.M. Flipo. 2007. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine 74: 56–59.CrossRef
53.
Woodruff, T.M., T.V. Arumugam, I.A. Shiels, R.C. Reid, D.P. Fairlie, and S.M. Taylor. 2003. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. Journal of Immunology 171(10): 5514–5520.
54.
Barbuio, R., M. Milanski, M.B. Bertolo, M.J. Saad, and L.A. Velloso. 2007. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. Journal of Endocrinology 194: 539–550.PubMedCrossRef
55.
Bush, K.A., B.W. Kirkham, and J.S. Walker. 2002. The in vivo effects of tumor necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis. Clinical & Experimental Immunology 127: 423–429.CrossRef
56.
Feige, U., Y.L. Hu, J. Gasser, G. Campagnuolo, L. Munyakazi, and B. Bolon. 2000. Anti-interleukin-1 and anti-tumour necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cellular and Molecular Life Sciences 57: 1457–1470.PubMedCrossRef
57.
Kim, E.Y., H.H. Chi, R. Rajaiah, and D.B. Moudgil. 2008. Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis. Arthritis Research & Therapy 10: R38.CrossRef
58.
Williams, R.O. 2008. Paradoxal effects of tumour necrosis factor-α in adjuvant arthritis. Arthritis Research & Therapy 10: 113.CrossRef
59.
Fathalla, B., K. Hamada, E. Vannier, D. Smith, C. Edwards, and R. Roubenoff. 2004. Effects of aging and cytokine blockade on inflammatory cachexia. Clinical and Experimental Rheumatology 22: 85–90.PubMed
Metadata
Title
Protective Effects of Indomethacin and Cyclophosphamide but Not of Infliximab on Liver Metabolic Changes Caused by Adjuvant-Induced Arthritis
Authors
Maria Angélica Raffaini Covas Pereira da Silva
Ciomar Aparecida Bersani-Amado
Emy Luiza Ishii-Iwamoto
Lívia Bracht
Silvana Martins Caparroz-Assef
Publication date
01-12-2011
Publisher
Springer US
Published in
Inflammation / Issue 6/2011
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9259-3

Other articles of this Issue 6/2011

Inflammation 6/2011 Go to the issue

OriginalPaper

Radon Inhalation Protects Mice from Carbon-Tetrachloride-Induced Hepatic and Renal Damage

OriginalPaper

Polymorphisms of the IL23R Gene Are Associated with Psoriasis but not with Immunoglobulin A Nephropathy in a Hungarian Population

OriginalPaper

Inflammation Alters Angiotensin Converting Enzymes (ACE and ACE-2) Balance in Rat Heart

OriginalPaper

Study of Programmed Cell Death 1 (PDCD1) Gene Polymorphims in Iranian Patients with Ankylosing Spondylitis

OriginalPaper

AV119, a Natural Sugar from Avocado gratissima, Modulates the LPS-Induced Proinflammatory Response in Human Keratinocytes

OriginalPaper

Fish Oil, but Not Soy Bean or Olive Oil Enriched Infusion Decreases Histopathological Severity of Acute Pancreatitis in Rats Without Affecting Eicosanoid Synthesis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits